Home / Market News / $HUM

$HUM news and market catalysts

The 50 most recent market catalysts affecting $HUM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

50 catalysts 8 high impact 33 bullish 5 bearish Healthcare
Nov 19, 2026 Corporate Catalyst Bearish Impact 85
Humana Shares Decline Amid Increased Regulatory Scrutiny of Government Health Programs
Humana Inc. experienced a significant share price drop of over 12% following investor apprehension regarding the new 'CRUSH' rule. This regulatory initiative aims to intensify over…
Nov 17, 2026 Corporate Catalyst Bearish Impact 85
Humana Shares Decline Following Proposed Medicare Advantage Audit Framework
Humana's stock declined over 5% on November 17, 2026, after the U.S. government proposed a new Medicare Advantage audit framework. This proposal is perceived by analysts as a negat…
Nov 17, 2026 Corporate Catalyst Bullish Impact 55
Humana to Launch National Gold Card Program
Humana is launching a national Gold Card program on December 1, 2026, to reduce prior authorization requirements for providers with a strong track record. This move is significant …
Nov 17, 2026 Corporate Catalyst Neutral Impact 55
Humana Announces Final Results of Cash Tender Offers for Outstanding Debt Securities
Humana Inc. has completed its previously announced cash tender offers for various series of its senior notes. This event signifies the successful execution of a debt refinancing or…
Nov 16, 2026 Corporate Catalyst Neutral Impact 55
Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Humana Inc. has disclosed the reference yield and total consideration for its cash tender offers to purchase specific outstanding notes. This is a standard corporate finance activi…
Nov 16, 2026 Corporate Catalyst Bullish Impact 65
Bernstein Adjusts Price Target on Humana to $515 From $425
Bernstein, an investment firm, has raised its price target for Humana Inc. from $425 to $515. This adjustment indicates a more favorable valuation assessment of the health insuranc…
Nov 11, 2026 Corporate Catalyst Bearish Impact 55
TD Cowen Adjusts Price Target on Humana
TD Cowen, an investment bank, has raised its price target for Humana Inc. from $370 to $430. This action indicates that the analyst firm now views Humana's future prospects more fa…
Nov 11, 2026 Corporate Catalyst Neutral Impact 55
Mizuho, TD Cowen, and Jefferies Adjust Price Targets on Humana
On November 11, 2026, Mizuho, TD Cowen, and Jefferies all raised their price targets for Humana Inc., indicating a more favorable view of the company's prospects. This matters as a…
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
Jefferies Adjusts Price Target on Humana to $520 From $420
Jefferies, a prominent financial firm, has significantly raised its price target for Humana Inc. from $420 to $520. This substantial increase indicates a strong positive re-evaluat…
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Adjusts Price Target on Humana
Piper Sandler has raised its price target for Humana (HUM) from $463 to $526 following the company's third-quarter earnings report and updated guidance. This analyst upgrade sugges…
Nov 10, 2026 Market Technicals Bullish Impact 55
Cantor Fitzgerald Raises Price Target on Humana
Cantor Fitzgerald updated its analyst note on Humana, raising its price target to $495 while keeping an Overweight rating. This move signals continued confidence in Humana's future…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Humana Commences Cash Tender Offers for Certain Outstanding Debt Securities
Humana Inc. announced it is commencing cash tender offers for certain outstanding debt securities. This is a common corporate finance strategy where a company buys back its own deb…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Barclays Raises Price Target on Humana to $587
Barclays updated its outlook on Humana, raising its price target by a modest 0.9% to $587 while reiterating an 'Overweight' rating. This adjustment signals continued confidence fro…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Analysts Adjust Price Targets and Ratings for Humana Inc.
On November 9, 2026, Humana Inc. received updated research from several financial firms. Deutsche Bank increased its price target to $516 from $436, while Piper Sandler raised its …
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Adjusts Price Target on Humana to $526 From $463
Piper Sandler has raised its price target for Humana Inc. (HUM) shares from $463 to $526. This upward revision indicates that the analyst firm has a more favorable valuation outloo…
Nov 6, 2026 Corporate Catalyst Bullish Impact 85
Humana Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Humana Inc. announced its Q3 2026 financial results, reporting revenue of $41.16 billion, which surpassed the FactSet consensus of $40.87 billion. Crucially, the company also raise…
Nov 3, 2026 Corporate Catalyst Bullish Impact 65
Humana and athenahealth Expand Electronic Prior Authorization Capabilities
Humana and athenahealth are expanding their existing collaboration to embed electronic prior authorization directly into athenahealth's clinical workflows. This matters because pri…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Humana Launches Precision-Prescribing Collaboration for Indiana Dual Eligibles
Humana has announced a new collaboration to implement precision-prescribing support for its dual-eligible members in Indiana. This is a strategic move to address medication failure…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on Humana, Raises Price Target to $495
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on Humana (HUM) and raised the price target from $468 to $495. This action signals a continued bullish sentiment from a p…
Oct 12, 2026 Market Technicals Bullish Impact 55
Truist Securities Maintains Hold on Humana, Raises Price Target to $475
Truist Securities analyst David Macdonald maintained a 'Hold' rating on Humana but raised the price target from $415 to $475. This indicates that while the analyst sees increased v…
Oct 12, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Humana, Raises Price Target to $525
Oppenheimer analyst Michael Wiederhorn maintained an 'Outperform' rating on Humana and raised the price target from $475 to $525. This action signals continued confidence in Humana…
Oct 12, 2026 Corporate Catalyst Bullish Impact 65
Raymond James Upgrades Humana to Outperform, Announces $520 Price Target
Raymond James analyst John Ransom upgraded Humana (HUM) from Market Perform to Outperform, simultaneously announcing a $520 price target. This upgrade signals increased confidence …
Oct 9, 2026 Corporate Catalyst Bullish Impact 85
Shares of health insurance companies are trading higher the U.S. CMS awarded five- and four-star ratings to plans offered by UnitedHealth Group, Clover, and Humana among others. Also, Humana reaffirmed its FY26 adjusted EPS guidance and issued optimistic comments about FY27 and FY28.
This headline is a significant corporate catalyst for the health insurance sector. The CMS star ratings directly impact Medicare Advantage plans' reimbursement rates and marketing …
Oct 9, 2026 Corporate Catalyst Bullish Impact 75
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Humana's significant improvement in Medicare Advantage Star Ratings is a major positive catalyst. These ratings directly impact a health insurer's ability to attract and retain mem…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Humana, Raises Price Target to $582
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Humana and raised the price target from $515 to $582. This action signals continued confidence in Humana's performa…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Humana, Raises Price Target to $475
Oppenheimer analyst Michael Wiederhorn has maintained an 'Outperform' rating on Humana and raised the price target from $405 to $475. This action signals a strong belief in Humana'…
Oct 9, 2026 Corporate Catalyst Bullish Impact 85
Humana Stock Hits 52-Week High After Medicare Ratings Boost
Humana's announcement of significantly improved Medicare Advantage Star Ratings for 2027 is a major positive catalyst. The fact that 95% of its members are now in plans rated four …
Oct 9, 2026 Corporate Catalyst Bullish Impact 65
This Humana Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
The filing reports multiple analyst upgrades across various sectors, with Humana (HUM) being the most prominent due to a substantial price target increase from $390 to $596 by Bair…
Oct 9, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Friday's Pre-Market Session
This 'filing' is actually a Benzinga article summarizing pre-market trading activity for various healthcare stocks. It's not an official SEC 8-K filing, which typically discloses m…
Oct 9, 2026 Corporate Catalyst Bullish Impact 85
Humana shares are trading higher after the CMS 2027 Medicare Advantage Part D Release awarded the company's largest contract a 4-star rating, making it eligible for bonus payments. The company reaffirmed its FY26 adjusted EPS guidance.
This news is a significant positive catalyst for Humana, directly impacting its profitability through bonus payments tied to the 4-star rating for its largest Medicare Advantage co…
Oct 9, 2026 Corporate Catalyst Neutral Impact 75
Humana FY2026 Adj EPS expected to be more than $9.00 vs $9.15 Est
Humana (HUM) has disclosed its updated expectation for fiscal year 2026 adjusted EPS, projecting it to be 'more than $9.00'. This is a significant piece of guidance as it sets the …
Oct 9, 2026 Corporate Catalyst Neutral Impact 55
Humana Reaffirms FY26 Adjusted EPS Guidance Of At Least $9; Exceeding Goal Of Top Quartile Results In 2027 Medicare Advantage Star Ratings; Expects 2028 Benefit For One-Time Investments And Return To Shareholders
Humana's 8-K filing reaffirms its previously issued FY26 Adjusted EPS guidance of at least $9.00. This is not new information, as the company explicitly states it's consistent with…
Oct 9, 2026 Corporate Catalyst Bullish Impact 65
Baird Upgrades Humana to Outperform, Raises Price Target to $596
Baird analyst Michael Ha upgraded Humana (HUM) from Neutral to Outperform and raised the price target from $390 to $596. This significant price target increase, representing a pote…
Oct 8, 2026 Corporate Catalyst Bullish Impact 85
Humana shares are trading higher after the CMS 2027 Medicare Advantage Part D Release awarded the company's largest contract a 4-star rating, making it eligible for bonus payments.
This news is a significant positive catalyst for Humana, as the 4-star rating directly translates to increased revenue through bonus payments from the Centers for Medicare & Medica…
Oct 7, 2026 Corporate Catalyst Bullish Impact 75
Cantor Fitzgerald Upgrades Humana to Overweight, Raises Price Target to $460
Cantor Fitzgerald's upgrade of Humana (HUM) from Neutral to Overweight, coupled with a substantial price target increase from $300 to $460, indicates a strong conviction from the a…
Sep 25, 2026 Corporate Catalyst Bullish Impact 75
Humana shares are trading higher after Barclays upgraded its rating on the stock from Equal-Weight to Overweight and raised its price target from $407 to $515.
This headline represents a significant corporate catalyst for Humana. An upgrade from Equal-Weight to Overweight by a major investment bank like Barclays, coupled with a substantia…
Sep 25, 2026 Corporate Catalyst Bullish Impact 65
Barclays Upgrades Humana to Overweight, Raises Price Target to $515
Barclays analyst Andrew Mok upgraded Humana (HUM) from Equal-Weight to Overweight and significantly raised the price target from $407 to $515. This upgrade reflects a more bullish …
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman's public endorsement of Mark Cuban's proposals for transparent drug pricing, which aim to dismantle the traditional PBM model, signals a significant shift in the health…
Sep 1, 2026 Corporate Catalyst Neutral Impact 65
Humana Reiterates FY26 Adjusted EPS Outlook Of At Least $9
Humana filed an 8-K to reiterate its adjusted EPS outlook of at least $9 for fiscal year 2026. This is a reaffirmation of previously communicated guidance, not new information. It …
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Neutral on Humana, Raises Price Target to $393
This filing indicates that JP Morgan analyst Lisa Gill has maintained a 'Neutral' rating on Humana (HUM) but significantly raised the price target from $316 to $393. This action si…
Aug 5, 2026 Corporate Catalyst Bullish Impact 65
Morgan Stanley Upgrades Humana to Equal-Weight, Raises Price Target to $370
Morgan Stanley analyst Erin Wright upgraded Humana (HUM) from Underweight to Equal-Weight and raised the price target from $249 to $370. This significant increase in the price targ…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Equal-Weight on Humana, Raises Price Target to $407
Barclays analyst Andrew Mok maintained an 'Equal-Weight' rating on Humana but significantly raised the price target from $344 to $407. This action signals a more optimistic valuati…
Jul 30, 2026 Corporate Catalyst Bullish Impact 65
Evercore ISI Group Upgrades Humana to Outperform, Raises Price Target to $480
This filing discloses that Evercore ISI Group has upgraded Humana's stock rating and raised its price target. This is a positive development for Humana as it signals increased conf…
Jul 30, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Humana, Raises Price Target to $471
Guggenheim analyst Jason Cassorla maintained a 'Buy' rating on Humana and substantially raised the price target from $269 to $471. This significant increase in the price target ind…
Jul 30, 2026 Corporate Catalyst Bearish Impact 65
Raymond James Downgrades Humana to Market Perform
Raymond James analyst John Ransom downgraded Humana (HUM) from Outperform to Market Perform. This change in rating suggests that the analyst believes Humana's stock will now perfor…
Jul 29, 2026 Corporate Catalyst Bearish Impact 85
Humana shares are trading lower after the company reported Q2 financial results and issued FY26 GAAP EPS guidance below estimates.
Humana's lower-than-expected Q2 results and, more critically, the reduced FY26 GAAP EPS guidance signal potential headwinds for the company's long-term profitability. This could st…
Jul 29, 2026 Corporate Catalyst Neutral Impact 75
Humana FY2026 GAAP EPS expected to be more than $6.52 vs $8.55 Est
Humana's 8-K filing reveals that the company anticipates its GAAP EPS for fiscal year 2026 to be more than $6.52. This figure is notably lower than the current analyst consensus es…
Jul 29, 2026 Corporate Catalyst Neutral Impact 75
Humana FY2026 Adj EPS expected to be more than $9.00 vs $8.94 Est
Humana has provided an updated outlook for its fiscal year 2026 adjusted EPS, projecting it to be above $9.00, which is slightly higher than the consensus estimate of $8.94. This g…
Jul 29, 2026 Corporate Catalyst Neutral Impact 65
Humana Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Humana is set to release its Q2 earnings, with analysts projecting strong growth in both EPS and revenue compared to the prior year. This positive outlook is reinforced by several …
Jul 14, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Hold on Humana, Raises Price Target to $350
TD Cowen's analyst Ryan Langston maintained a 'Hold' rating on Humana but substantially raised the price target from $211 to $350. This significant increase in the price target, de…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.